Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FENOGLIDE vs ATROMID-S
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It increases lipolysis and elimination of triglyceride-rich particles from plasma, reduces hepatic production of VLDL, and increases HDL cholesterol.
Inhibits hepatic triglyceride synthesis and increases lipoprotein lipase activity, leading to reduced VLDL and triglycerides.
Primary hypercholesterolemia,Mixed dyslipidemia,Severe hypertriglyceridemia
Type III hyperlipoproteinemia,Hypertriglyceridemia (Fredrickson types IV and V) not responsive to diet
160 mg orally once daily, taken with or without food.
500 mg to 1 g orally twice daily. Maximum dose 2 g/day.
The terminal elimination half-life of fenofibric acid is approximately 20 hours (range 15-25 hours). This long half-life allows once-daily dosing. Steady-state is reached within approximately 5 days.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; may be prolonged to 12-24 hours in renal impairment.
Hepatic metabolism via glucuronidation; minor CYP450 involvement (CYP3A4).
Hepatic via glucuronidation and oxidation; major metabolite is clofibric acid.
Fenoglide (fenofibrate) is primarily excreted in urine as fenofibric acid and its glucuronide conjugate, accounting for approximately 60-70% of the dose. About 20-25% is eliminated in feces via biliary excretion. Renal excretion is the major route.
Primarily renal excretion as glucuronide conjugates; approximately 60-70% of the dose is excreted in urine, 20-30% in feces via biliary elimination.
Fenofibric acid is extensively bound to plasma proteins, primarily albumin, with a binding rate greater than 99%.
>95% bound to plasma proteins, primarily albumin.
The apparent volume of distribution (Vd) of fenofibric acid is approximately 0.9 L/kg. This suggests distribution into total body water, with some tissue binding.
0.11-0.14 L/kg; low Vd indicates limited extravascular distribution, consistent with high protein binding.
The absolute oral bioavailability of fenofibric acid from fenofibrate tablets is approximately 90% under fed conditions. Administration with food increases absorption by up to 35% compared to fasting.
Oral: approximately 60-70% due to first-pass metabolism; administered as clofibrate (prodrug) which is hydrolyzed to active clofibric acid.
No dose adjustment required for mild to moderate renal impairment (e GFR >30 m L/min/1.73 m2). Not recommended in severe renal impairment (e GFR <30 m L/min/1.73 m2) or dialysis.
GFR 30-59 m L/min: 500 mg twice daily. GFR 15-29 m L/min: 250 mg twice daily. GFR <15 m L/min: avoid use.
Contraindicated in severe hepatic impairment (Child-Pugh class C). Use caution in moderate impairment (Child-Pugh class B); consider dose reduction.
Child-Pugh Class B or C: avoid use or reduce dose by at least 50%; not recommended in severe hepatic impairment.
Not approved for use in pediatric patients under 18 years of age.
Not recommended; safety and efficacy not established in pediatric patients.
No specific dose adjustment; monitor renal function due to age-related decline.
Start at lower end of dosing range (500 mg twice daily). Monitor renal function; adjust dose based on GFR.
No FDA black box warning.
None
Hepatotoxicity: rare but severe; monitor liver enzymes.,Rhabdomyolysis: risk increased with renal impairment, hypothyroidism, statins.,Renal function: dose adjustment needed in mild-moderate impairment; contraindicated in severe renal disease.,Cholelithiasis: fenofibrate increases cholesterol excretion into bile.,Pancreatitis: associated with severe hypertriglyceridemia; monitor triglycerides.,Venous thromboembolism: increased risk with fenofibrate.
Hepatotoxicity,Cholelithiasis,Renal impairment dose adjustment,Rhabdomyolysis risk with statins,Malignancy risk (hepatic, GI)
Severe renal impairment (e GFR <30 m L/min/1.73m²),Active liver disease including primary biliary cirrhosis,Known hypersensitivity to fenofibrate or excipients,Gallbladder disease,Nursing mothers
Hypersensitivity to clofibrate,Active liver disease,Severe renal dysfunction,Primary biliary cirrhosis,Pregnancy
Take with food to enhance absorption. Avoid high-fat meals immediately before or after dose. Grapefruit juice may increase fenofibrate exposure (moderate interaction, monitor). Statin co-administration: avoid large amounts of grapefruit juice.
High-fat meals may reduce absorption; consistent timing of administration with food is recommended. Grapefruit juice may increase drug levels; avoid excessive intake. Alcohol may exacerbate hepatotoxicity.
First trimester: No adequate studies; animal data show no major malformations at clinically relevant doses. Second and third trimesters: Associated with adverse maternal and fetal outcomes (e.g., preterm birth, low birth weight) due to β-receptor agonist effects. Avoid use during pregnancy.
FDA Pregnancy Category C. First trimester: Potential for teratogenicity based on animal studies showing skeletal and visceral anomalies. Human data limited; use only if benefit outweighs risk. Second and third trimesters: May cause fetal harm due to placental transfer and potential for reduced fetal growth.
Excreted in breast milk; M/P ratio unknown. Potential for neonatal β-receptor stimulation. Caution advised; manufacturer recommends discontinuing breastfeeding or drug.
Excreted into breast milk in low amounts; M/P ratio not established. Due to potential for serious adverse effects in infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
No established dose adjustments for pregnancy; use only if potential benefit outweighs risk. Consideration of lower doses due to altered pharmacokinetics (increased clearance, decreased plasma concentration).
No specific dosing adjustments recommended due to lack of data. However, pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) may necessitate careful monitoring and empiric dose adjustments based on clinical response and adverse effects.
Fenofibrate is a fibric acid derivative used primarily for hypertriglyceridemia and mixed dyslipidemia. It activates PPAR-alpha, increasing lipoprotein lipase and reducing apolipoprotein C-III. Monitor renal function; dose adjustment required for Cr Cl 30-60 m L/min. Contraindicated in severe renal impairment (Cr Cl <30) and active liver disease. Can increase serum creatinine, but this is often reversible. Co-administration with statins increases risk of myopathy, especially in elderly or renal impairment. May increase homocysteine levels; monitor if at risk for thrombosis.
ATROMID-S (clofibrate) is a fibric acid derivative primarily indicated for hyperlipidemia but its use is now limited due to increased non-cardiovascular mortality and cholelithiasis risk. Monitor liver function and prothrombin time (potentiates warfarin). Not first-line; consider statins or fibrates like fenofibrate.
Take with food to improve absorption.,Avoid alcohol as it may worsen triglyceride levels.,Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise.,Do not stop medication without consulting your doctor, even if you feel well.,Keep all appointments for blood tests to monitor liver function and lipid levels.
Take with meals to reduce gastrointestinal upset.,Report unexplained muscle pain, tenderness, or weakness; may indicate myopathy.,Avoid alcohol as it may increase liver enzyme elevations.,Notify your doctor if you develop gallstones symptoms (e.g., right upper abdominal pain, nausea).,Use effective contraception as clofibrate may cause fetal harm.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FENOGLIDE vs ATROMID-S, answered by our medical review team.
FENOGLIDE is a Antilipemic that works by Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It increases lipolysis and elimination of triglyceride-rich particles from plasma, reduces hepatic production of VLDL, and increases HDL cholesterol.. ATROMID-S is a Antilipemic Agent that works by Inhibits hepatic triglyceride synthesis and increases lipoprotein lipase activity, leading to reduced VLDL and triglycerides.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FENOGLIDE and ATROMID-S depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FENOGLIDE is: 160 mg orally once daily, taken with or without food.. The standard adult dose of ATROMID-S is: 500 mg to 1 g orally twice daily. Maximum dose 2 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FENOGLIDE and ATROMID-S in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FENOGLIDE is classified as Category C. First trimester: No adequate studies; animal data show no major malformations at clinically relevant doses. Second and third trimesters: Associated with adverse maternal and fetal . ATROMID-S is classified as Category C. FDA Pregnancy Category C. First trimester: Potential for teratogenicity based on animal studies showing skeletal and visceral anomalies. Human data limited; use only if benefit out. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.